Degraders of CDK2 and KRAS follow the group's attempts at inhibiting these targets.
ApexOnco Front Page
Recent articles
Adverse events will be closely watched when full data are reported.
LY4170156 looks similar to Genmab’s rina-S, but cost Lilly a lot less.
Bristol buys into the frenzy, and VEGF bispecific value inflation continues.
As patritumab-dxd's problems mount, Astra's decision to say no to this project looks smart.
The company highlights the safety of its KLK2-targeting T-cell engager pasritamig.
But camizestrant’s use could depend on uptake of monitoring – for now.
Any hopes of differentiation could come down to side effects.
